Walser Wealth Management Company A Ltd Liability Co Invests $592,000 in Bristol Myers Squibb Company $BMY

Posted by Brian Himes on Jul 7th, 2026

Walser Wealth Management Company A Ltd Liability Co bought a new stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 9,758 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

Other large investors have also recently bought and sold shares of the company. Cypress Capital LLC grew its position in Bristol Myers Squibb by 21.1% during the 1st quarter. Cypress Capital LLC now owns 46,061 shares of the biopharmaceutical company’s stock worth $2,794,000 after purchasing an additional 8,019 shares during the last quarter. Meridian Investment Counsel Inc. purchased a new stake in shares of Bristol Myers Squibb in the first quarter valued at about $217,000. Kathmere Capital Management LLC boosted its stake in shares of Bristol Myers Squibb by 125.1% during the first quarter. Kathmere Capital Management LLC now owns 23,174 shares of the biopharmaceutical company’s stock worth $1,406,000 after buying an additional 12,880 shares during the period. Abel Hall LLC grew its holdings in shares of Bristol Myers Squibb by 3.6% during the first quarter. Abel Hall LLC now owns 21,100 shares of the biopharmaceutical company’s stock worth $1,280,000 after buying an additional 735 shares during the last quarter. Finally, Whittier Trust Co. grew its holdings in shares of Bristol Myers Squibb by 2.5% during the first quarter. Whittier Trust Co. now owns 57,283 shares of the biopharmaceutical company’s stock worth $3,399,000 after buying an additional 1,377 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of BMY traded up $1.57 during mid-day trading on Tuesday, hitting $58.27. The company’s stock had a trading volume of 2,245,915 shares, compared to its average volume of 12,378,629. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. The firm has a 50-day simple moving average of $56.90 and a 200 day simple moving average of $57.51. The firm has a market capitalization of $118.99 billion, a P/E ratio of 16.37, a P/E/G ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.Bristol Myers Squibb’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.32 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 70.79%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BMY. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Bank of America dropped their price objective on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Finally, HSBC raised their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday, March 17th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $61.31.

Read Our Latest Stock Analysis on BMY

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.